The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
Open accessAbstract
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Cited by
A taxonomy of model structures for economic evaluation of health technologies
Brennan, A., Chick, S. E., & Davies, R. (2006) · Health Economics · doi:10.1002/hec.1148 · Cited by 555
Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J. C., Luisa Brandi, M., Bruyère, O., Guillemin, F., Hochberg, M. C., Hunter, D. J., et al. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.07.003 · Cited by 327
Decision-making in priority setting for medicines—A review of empirical studies
Vuorenkoski, L., Toiviainen, H., & Hemminki, E. (2008) · Health Policy · doi:10.1016/j.healthpol.2007.09.007 · Cited by 62
Pichon-Riviere, A., Augustovski, F., Bardach, A., & Colantonio, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.05.010 · Cited by 43
Metadata
- Authors
- Taylor, R. S., Drummond, M. F., Salkeld, G., & Sullivan, S. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-10-21
- Volume
- 329
- Issue
- 7472
- Pages
- 972-975
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2031244180
- Cited by
- 194
- References
- 1
- FWCI
- 37.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. https://app.cochat.ai/papers/10.1136/bmj.329.7472.972
- The paper
- Taylor, R. S., Drummond, M. F., Salkeld, G., & Sullivan, S. D. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. https://doi.org/10.1136/bmj.329.7472.972
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.